Recent Updates — CRL

Charles River Laboratories International, Inc. issued a press release on September 24, 2026, during its Investor Day to outline the 'Pathway to Purpose' strategic vision aimed at modernizing operations and strengthening its scientific portfolio. The company reaffirmed its full-year 2026 guidance, expecting revenue and non-GAAP earnings per share at the upper ends of prior ranges ($11.45). It introduced long-term financial targets through 2030, including a 5%–7% organic revenue CAGR (2027-2030), approximately 24% non-GAAP operating margin, and low-double-digit non-GAAP EPS growth. Additionally, the firm expects over $300 million in cumulative savings from its 'Create the Future' efficiency program between 2027 and 2030. Charles River Laboratories International, Inc. operates in the biotechnology industry, providing essential products and services to accelerate pharmaceutical research and drug development.

Charles River Laboratories International, Inc. reported second-quarter 2026 financial results for the period ended June 27, 2026. The company generated revenue of $1.00 billion, a decrease of 2.7% from the prior year, with organic growth of 0.1%. GAAP diluted earnings per share were $(0.03), reflecting a $63.7 million loss on divestitures, while non-GAAP diluted EPS was $3.02. The company raised its full-year 2026 guidance, increasing revenue growth expectations by 150 basis points and non-GAAP EPS midpoint by $0.25, driven by improving demand in the Discovery and Safety Assessment segment and better-than-expected Manufacturing Solutions performance. Charles River repurchased $100 million of common stock during the quarter and completed divestitures of its CDMO and Cell Solutions businesses earlier in the year. The company operates in the pharmaceutical contract research organization (CRO) industry, providing preclinical testing, drug discovery, and development services.